Literature DB >> 26562821

Causes and Timing of Unplanned Early Readmission After Neurosurgery.

Blake E S Taylor1, Brett E Youngerman, Hannah Goldstein, Daniel H Kabat, Geoffrey Appelboom, William E Gold, Edward Sander Connolly.   

Abstract

BACKGROUND: Reducing the rate of 30-day hospital readmission has become a priority in healthcare quality improvement policy, with a focus on better characterizing the reasons for unplanned readmission. In neurosurgery, however, peer-reviewed analyses describing the patterns of readmission have been limited in their number and generalizability.
OBJECTIVE: To determine the incidence, timing, and causes of 30-day readmission after neurosurgical procedures.
METHODS: We conducted a retrospective longitudinal study from 2009 to 2012 using the Statewide Planning And Research Cooperative System, which collects patient-level details for all admissions and discharges within New York. We identified patients readmitted within 30 days of initial discharge. The rate of, reasons for, and time to readmission were determined overall and within 4 subgroups: craniotomies, cranial surgery without craniotomy, spine, and neuroendovascular procedures.
RESULTS: There were 163 743 index admissions, of whom 14 791 (9.03%) were readmitted. The most common reasons for unplanned readmission were infection (29.52%) and medical complications (19.22%). Median time to readmission was 11 days, with hemorrhagic strokes and seizures occurring earlier, and medical complications and infections occurring later. Readmission rates were highest among patients undergoing cerebrospinal fluid shunt revision and malignant tumor resection (15.57%-22.60%). Spinal decompressions, however, accounted for the largest volume of readmissions (33.13%).
CONCLUSION: Many readmissions may be preventable and occur at predictable time intervals. The causes and timing of readmission vary significantly across neurosurgical subgroups. Future studies should focus on detecting specific complications in select cohorts at predefined time points, which may allow for interventions to lower costs and reduce patient morbidity. ABBREVIATIONS: CSF, cerebrospinal fluidIQR, interquartile rangeSPARCS, Statewide Planning And Research Cooperative System.

Entities:  

Mesh:

Year:  2016        PMID: 26562821     DOI: 10.1227/NEU.0000000000001110

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  5 in total

1.  Causes of hospital readmissions within 7 days from the neurosurgical service of a quaternary referral hospital.

Authors:  Enyinna L Nwachuku; Kevin P Patel; Audrey L Paul; Robert M Friedlander; Peter C Gerszten
Journal:  Surg Neurol Int       Date:  2020-08-01

2.  Smoking and Obesity are Risk Factors for Thirty-Day Readmissions Following Skull Base Surgery.

Authors:  Milan Makwana; Peter N Taylor; Benjamin T Stew; Geoffrey Shone; Caroline Hayhurst
Journal:  J Neurol Surg B Skull Base       Date:  2019-04-02

3.  Readmission after neurosurgical intervention in epilepsy: A nationwide cohort analysis.

Authors:  Churl-Su Kwon; Parul Agarwal; Varsha Subramaniam; Mandip Dhamoon; Madhu Mazumdar; Anusha Yeshokumar; Fedor Panov; Saadi Ghatan; Nathalie Jetté
Journal:  Epilepsia       Date:  2019-12-02       Impact factor: 5.864

4.  Predictors of 30- and 90-day readmission following craniotomy for malignant brain tumors: analysis of nationwide data.

Authors:  Daniel A Donoho; Timothy Wen; Robin M Babadjouni; William Schwartzman; Ian A Buchanan; Steven Y Cen; Gabriel Zada; William J Mack; Frank J Attenello
Journal:  J Neurooncol       Date:  2017-10-07       Impact factor: 4.130

5.  Thirty- and 90-day Readmissions After Spinal Surgery for Spine Metastases: A National Trend Analysis of 4423 Patients.

Authors:  Aladine A Elsamadicy; Andrew B Koo; Wyatt B David; Cheryl K Zogg; Adam J Kundishora; Christopher S Hong; Gregory A Kuzmik; Ramana Gorrepati; Pedro O Coutinho; Luis Kolb; Maxwell Laurans; Khalid Abbed
Journal:  Spine (Phila Pa 1976)       Date:  2021-06-15       Impact factor: 3.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.